Loading data for TRAX — first visit, this takes a few seconds.

First Tracks Biotherapeutics, Inc. (TRAX)

NasdaqGS: TRAX · Real-Time Price · USD

41.86

-2.88 (-6.44%)

At close: Sep 03, 2026, 8:00 PM

42.75

+0.56%

Pre-market: 8:03 AM

Alert

The price, the headline numbers and the latest news, in one place.

No data available

Bid	42.45
Market Cap	1.52B
Revenue (ttm)	n/a
Net Income (ttm)	-160M
	0.00
	-4.42
	n/a
	-11.6
P/B (ttm)	8.91
P/S (ttm)	0.00
Earnings Date	Nov 5, 2026

Ask	55.34
Volume	409,886
Avg. Volume (20D)	769,901
Open	44.36
Previous Close	44.74
Day's Range	41.69 - 44.61
52-Week Range	14.72 - 49.91
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About TRAX

First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States. Its products includes ANB033, a novel anti-CD122 antagonist that targets the shared beta subunit of the IL-15 and IL-2 receptors; Rosnilimab, a antibody engineered to selectively deplete pathogenic T cells in both the periphery and inflamed tissues; and ANB101, ...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Apr 6, 2026

Employees 104

Stock Exchange NasdaqGS

Ticker Symbol TRAX

Website https://www.firsttracksbio.com

Full Company Profile

Financial Performance

In 2024, First Tracks Biotherapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -163.71M, an increase of 54.22%.

Financial Statements

Earnings Surprise

First Tracks Biotherapeutics has released their quarterly earnings on Aug 12, 2026:

Revenue of $0 misses estimates by $0, with NaN% YoY growth.
EPS of -0.95 misses estimates by -0.15, with -Infinity% YoY decline.

Next Earnings Release

First Tracks Biotherapeutics, Inc. is scheduled to release its earnings on Nov 5, 2026, during market hours.
Analysts project revenue of ... Upgrade

Why Price Moved

News

1 month ago · Stocktwits

TRAX Stock Hits All-Time High — What's Driving The Super Rally?

According to TheFly, HC Wainwright raised its price target on First Tracks to $44 from $30 while maintaining a ‘Buy’ rating.

3 months ago · Simply Wall St.

How The Grupo Traxión (BMV:TRAXION A) Story Is Shifting With Cautious New Analyst Targets

Grupo Traxión is in focus after a major global bank cut its MX$ price target by MX$6, pointing to a more restrained view on the stock. The shift lines up with recent research that adopts a more cautio...

3 months ago · Insider Monkey

Is AnaptysBio (ANAB) One of the Best Performing Healthcare Stocks so Far in 2026?

AnaptysBio, Inc. (NASDAQ:ANAB) is one of the best performing healthcare stocks so far in 2026. Piper Sandler cut the price target on AnaptysBio, Inc. (NASDAQ:ANAB) to $93 from $95 on May 4, reaffirmin...

5 months ago · MT Newswires

AnaptysBio Board Approves Spin-Off of First Tracks Bio, Repurchase of $100 Million Shares

AnaptysBio's (ANAB) board has approved the planned spin-off of First Tracks Biotherapeutics and a re

First Tracks Biotherapeutics, Inc. (TRAX)